久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Companies

Merck Serono looks to expand value chain

By Liu Jie (China Daily)
Updated: 2011-03-29 13:23
Large Medium Small

BEIJING - The biopharmaceutical company Merck Serono AG says mergers and acquisitions (M&A) will play a part in its development strategy in China, as the company seeks to complete its industry value chain and expand into the grassroots market.

Howard Sui, chairman and president of Merck Serono China Co Ltd, told China Daily on Monday that the company already has a research and development (R&D) center and a trading company in China, and is now seeking businesses engaged in manufacturing and distribution.

"We are selecting information and have had contact with some Chinese companies, but no decision has yet been made," said Sui.

Merck Serono looks to expand value chain

Howard Sui, chairman and president of Merck Serono China Co Ltd

Merck Serono, the prescription medicine division of the global pharmaceuticals and chemicals group Merck KGaA, has annually maintained sales growth of more than 30 percent in China since entering the market in 2007.

Merck Serono set up a trading company in Beijing with an investment of 300 million yuan ($45 million). Its Asian R&D center was established in November 2009, at a cost of 150 million euros ($211 million).

However, the company has no production capability in China, because it lacks the facilities in the market.

"We plan to establish a manufacturing facility in Beijing later this year after a decision was made when the group's senior executives visited China in 2010. The internal approval procedure is expected to be finalized next month," said Sui, without revealing the amount of investment in the new plant, or its production capability.

He also said that M&A activity will combine with organic growth to support the development of the company over the long term.

Merck Serono has introduced 18 drug brands in nine separate fields, treating conditions in the cardiovascular, thyroid, and women's health and fertility fields. The treatments are available at key hospitals in cities nationwide though partnerships with domestic distribution companies.

"If Merck Serono can buy a distributor, it will help the drugmaker to reach the grassroots markets at a relatively low cost," said Li Yu, a researcher at the Samsung Economic Research Institute China.

Related readings:
Merck Serono looks to expand value chain China lures global drug makers
Merck Serono looks to expand value chain Merck begins work on new unit
Merck Serono looks to expand value chain Lilly to continue China expansion
Merck Serono looks to expand value chain Novartis gets stake approval

Merck Serono's parent group has successfully employed an M&A strategy in China. In January, Merck KGaA bought Beijing Skywing Technology Co Ltd, a biopharmaceutical company, for 120 million yuan. In September 2009, it also acquired Suzhou Taizhu Technology Co Ltd, an effect pigment supplier based in Jiangsu province, for 28 million euros to expand its chemical business portfolio.

Merck KGaA has also been active in global M&A. Its latest move is the acquisition of Millipore Corp - a Massachusetts-based biopharmaceutical and life sciences company - in June.

That helped the German group lift its full-year profits and exceed analysts' expectations. The 2010 fiscal year saw post-tax profit climbing 70 percent to 642 million euros.

In 2007, Merck KGaA paid $13.3 billion to acquire Serono, at the time Europe's largest biopharmaceutical company by sales, and establish the Merck Serono joint venture. That deal helped the company to grow its China business by nine or 10 times between 2007 and 2009.

Multinational pharmaceutical companies have recently been conducting an aggressive M&A campaign in China. On March 22, the Swiss drugmaker Novartis AG announced that it had completed the acquisition of an 85 percent stake in Zhejiang-based Tianyuan Bio-Pharmaceutical Co Ltd for 850 million yuan.

France's Sanofi-Aventis SA bought BMP Sunstone Corporation for approximately $521 million in the largest M&A deal in China's pharmaceutical industry.

 

分享按鈕
主站蜘蛛池模板: 欧美在线一级毛片观看 | 91伦理视频 | 九九九九精品视频在线播放 | 久草免费看 | 亚洲精品日本高清中文字幕 | 亚洲羞羞视频 | 看真人一级毛片 | 亚洲自偷| 久久99国产亚洲高清观看韩国 | 成人免费网址在线 | 一区二区三区视频网站 | 午夜免费的国产片在线观看 | 太平公主三级dvd | 九草视频在线 | 国产精品日韩欧美在线第3页 | 国产一区二区三区不卡在线观看 | 一级做a爱久久久久久久 | 国产精品27页 | 亚洲三级黄色 | 色悠久久久久综合网伊人男男 | ab毛片 | 美女张腿男人桶免费视频 | 国产在线精品福利一区二区三区 | 2022麻豆福利午夜久久 | 欧美一级毛片欧美毛片视频 | 女人张开腿让男人插 | 日韩三级在线观看视频 | 99视频精品全国免费 | 国产精品二区页在线播放 | 在线免费一区二区 | 亚洲精品福利一区二区三区 | 高清不卡一区二区三区 | 久久成年人视频 | 日本成人中文字幕 | 国产一级爱c片免费播放 | 国产深夜福利视频观看 | 视频二区 中文字幕 欧美 | 香港av三级 | 欧美一级视频在线观看 | 夜夜躁狠狠躁日日躁2021 | 永久免费精品视频 |